肝硬化合并房颤患者抗凝治疗与死亡率及肝功能失代偿
该回顾性纵向研究纳入美国128家医疗中心2012至2017年新发房颤的肝硬化退伍军人,随访至2018年底。经倾向评分匹配和边缘结构模型分析,华法林和直接口服抗凝药(DOAC)均与全因死亡率降低相关,DOAC出血风险低于华法林。
要点
- 华法林和DOAC均与肝硬化合并房颤患者全因死亡率降低相关。
- DOAC与华法林相比出血风险更低,但属探索性分析。
- 抗凝治疗与缺血性卒中风险降低相关。
核心结论
- 华法林和DOAC均与全因死亡率降低相关。
- 华法林与不抗凝相比出血更多。
- 探索性分析中DOAC出血发生率低于华法林。
研究设计与样本
- 回顾性纵向研究,使用美国退伍军人全国数据,覆盖128家医疗中心。
- 纳入2012年1月1日至2017年12月31日新发房颤的肝硬化患者,随访至2018年12月31日。
- 最终队列2694例,倾向评分匹配后华法林组1694例、DOAC组704例,中位随访4.6年。
- 采用倾向评分匹配和边缘结构模型(MSM)控制适应证混杂和时间依赖混杂。
主要发现
- 华法林 versus 不抗凝:全因死亡率PS匹配HR 0.65(95%CI 0.55-0.76),MSM模型HR 0.54(95%CI 0.40-0.73)。
- DOAC versus 不抗凝:全因死亡率PS匹配HR 0.68(95%CI 0.50-0.93),MSM模型HR 0.50(95%CI 0.31-0.81)。
- MSM模型中,华法林与缺血性卒中减少相关(HR 0.29,95%CI 0.09-0.90),DOAC同样相关(HR 0.23,95%CI 0.07-0.79)。
- 次要分析中,DOAC与华法林相比出血风险更低(HR 0.49,95%CI 0.26-0.94)。
临床怎么用
- 肝硬化合并房颤患者启动抗凝前应综合评估卒中与出血风险。
- DOAC可能作为出血风险较高患者的优先选择,但需结合个体情况。
局限性
- 为回顾性研究,存在残余混杂可能。
- 研究人群为美国退伍军人,外推需谨慎。
- DOAC与华法林出血比较为探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Outcomes with anticoagulation (AC) are understudied in advanced liver disease. We investigated effects of AC with warfarin and direct oral anticoagulants (DOACs) on all-cause mortality and hepatic decompensation as well as ischemic stroke, major adverse cardiovascular events, splanchnic vein thrombosis, and bleeding in a cohort with cirrhosis and atrial fibrillation (AF). APPROACH AND RESULTS: This was a retrospective, longitudinal study using national data of U.S. veterans with cirrhosis at 128 medical centers, including patients with cirrhosis with incident AF, from January 1, 2012 to December 31, 2017 followed through December 31, 2018. To assess the effects of AC on outcomes, we applied propensity score (PS) matching and marginal structural models (MSMs) to account for confounding by indication and time-dependent confounding. The final cohort included 2,694 veterans with cirrhosis with AF (n = 1,694 and n = 704 in the warfarin and DOAC cohorts after PS matching, respectively) with a median of 4.6 years of follow-up. All-cause mortality was lower with warfarin versus no AC (PS matched: hazard ratio [HR], 0.65; 95% confidence interval [CI], 0.55-0.76; MSM models: HR, 0.54; 95% CI, 0.40-0.73) and DOACs versus no AC (PS matched: HR, 0.68; 95% CI, 0.50-0.93; MSM models: HR, 0.50; 95% CI, 0.31-0.81). In MSM models, warfarin (HR, 0.29; 95% CI, 0.09-0.90) and DOACs (HR, 0.23; 95% CI, 0.07-0.79) were associated with reduced ischemic stroke. In secondary analyses, bleeding was lower with DOACs compared to warfarin (HR, 0.49; 95% CI, 0.26-0.94). CONCLUSIONS: Warfarin and DOACs were associated with reduced all-cause mortality. Warfarin was associated with more bleeding compared to no AC. DOACs had a lower incidence of bleeding compared to warfarin in exploratory analyses. Future studies should prospectively investigate these observed associations.
引用
- Serper M, Weinberg EM, Cohen JB, et al. Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation. Hepatology. 2020. PMID: 32267547. doi:10.1002/hep.31264
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。